Roivant Sciences Ltd. ROIV 深 沪
等待开盘 08-17 09:30:00 美东时间
36.20
-0.080
-0.22%
华盛通- 最 高36.49
- 今 开36.135
- 成交量 452.73万股
- 最 低 35.87
- 昨 收 36.28
- 总市值 261.48亿
- 52周最高 37.00
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 11.60
- 委 比 69.88%
- 总股本 7.22亿
- 历史最高 37.00
- 量 比 0.72
- 振 幅 1.71%
- 历史最低 2.52
- 每 手 1
- 风险率 6.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
08-15 01:35
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $34 to $41.
08-07 21:12
财报速睇 | Roivant Sciences Ltd. 2026财年Q2营收0.01亿美元，同比下降33.5%；归母净利润亏损1.90亿美元，同比亏损缩窄15.0%
华盛资讯8月6日讯，Roivant Sciences Ltd.公布2026财年Q2业绩，公司Q2营收0.01亿美元，同比下降33.5%，归母净利润亏损1.90亿美元，同比亏损缩窄15.0%。
08-06 21:59
财报速睇 | Roivant Sciences Ltd. 2026财年Q2营收0.01亿美元，同比下降33.5%；归母净利润亏损1.90亿美元，同比亏损缩窄15.0%
华盛资讯8月6日讯，Roivant Sciences Ltd.公布2026财年Q2业绩，公司Q2营收0.01亿美元，同比下降33.5%，归母净利润亏损1.90亿美元，同比亏损缩窄15.0%。
08-06 19:51
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $1.442 million ...
08-06 19:12
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant, Inc. announced it will report its Q1 2026 financial results on August 6, 2026 before the market opens. Roivant Sciences Ltd., Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that day, including a business update for Immunovant. Registration links and details are available on the Immunovant website.
07-23 20:05
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under th...
07-16 19:39
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Biopharma and its licensee, Genevant, filed international lawsuits against Pfizer and BioNTech to enforce their lipid nanoparticle (LNP) patents. Arbutus received $178M from Moderna as part of a settlement for patent infringement. The company expects a dividend from Genevant in Q3 2026 and plans to return up to $230M to shareholders through share repurchases.
07-16 11:30
